ORGANOGENESIS HOLDINGS INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$6.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2021-03-16
- ORGANOGENESIS HOLDINGS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was -$6.00M, a 184.91% decline from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was $7.07M, a 50.30% decline from fiscal 2018.
- ORGANOGENESIS HOLDINGS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2018 was $14.21M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2020-12-31 | -$6.00M 10-K · filed 2021-03-16 |
| 2019-12-31 | $7.07M 10-K · filed 2020-03-09 |
| 2018-12-31 | $14.21M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |